At what lower end of recurrence risk do you offer adjuvant imatinib for patients with resected GIST?

The "lower end of recurrence risk" justifying adjuvant Imatinib is indeed a personalized decision between the provider and the patient based on risk-tolerance on both sides. In the absence of "cost-effectiveness" data, this has to be a mutual decision that works for both sides. In general, <20% risk...